Wnt/β-catenin-IN-6

Wnt/β-catenin-IN-6 is an orally active Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun) . Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research[1].

Product Specifications

UNSPSC

12352211

Target

Akt; Apoptosis; c-Myc; COX; EGFR; ERK; GSK-3; Interleukin Related; JNK; Wnt; β-catenin

Related Pathways

Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Purity

98.34

Solubility

DMSO : 5.83 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

COC1=C(OCC2=CC=CC=C2)C=C(N=CN=C3NC4=CC=C(NC(C=C)=O)C=C4)C3=C1

Molecular Formula

C25H22N4O3

Molecular Weight

426.47

References & Citations

[1]Zhao M, et al. A novel Quinazoline derivative exerts anti-tumor effects in non-small cell lung cancer through Wnt/β-catenin pathway inhibition. Bioorg Chem. 2025 Jun 15;160:108481.